ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

DNA

Pfizer licenses Akcea antisense therapy

by Lisa M. Jarvis
October 12, 2019 | APPEARED IN VOLUME 97, ISSUE 40

 

Pfizer is paying $250 million to license an antisense therapy in Phase II studies to treat diabetes, hypertriglyceridemia, and nonalcoholic fatty liver disease. The sellers are Ionis Pharmaceuticals and its affiliate Akcea Therapeutics. AKCEA-ANGPTL3-LRx lowers levels of a liver protein, angiopoietin-like 3 (ANGPTL3), that helps control triglycerides, cholesterol, glucose, and energy metabolism. People with a genetic mutation that causes lower-than-normal ANGPTL3 levels have a lower risk of diabetes and heart disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment